- AGC completed the acquisition of Malgrat Pharma Chemicals, announced on December 4, 2018.
- Financial results from the acquisition will be reflected in AGC's consolidated accounts from 1Q FY2019.
- AGC aims to generate sales of over 65 billion yen in 2020 and over 100 billion yen in 2025.
- MPC meets cGMP standards and has a strong production track record.
Acquisition Completion
AGC, headquartered in Tokyo, has completed the acquisition of the synthetic pharmaceutical active ingredient manufacturing plant, Malgrat Pharma Chemicals, S.L.U. (MPC). The acquisition was initially announced on December 4, 2018, and the financial results will be included in AGC's consolidated accounts starting from the first quarter of FY2019.
Manufacturing Capabilities
With MPC, AGC can now manufacture and process intermediates for synthetic pharmaceuticals up to active ingredients in Europe. This complements AGC's existing capabilities in Japan, where it has been serving pharmaceutical customers with its fluorine technology and in-house drug discovery expertise. MPC adheres to cGMP standards and has a robust production history, capable of handling various scales from development to commercial stage pharmaceuticals.
Strategic Goals
AGC aims to increase its presence in the European market, where demand for synthetic pharmaceuticals is expected to grow significantly. The company plans to expand its Contract Development and Manufacturing Organization (CDMO) business globally. Under its AGC plus management policy, the AGC Group targets sales of over 65 billion yen in 2020 and over 100 billion yen in 2025.
Future Investments
The acquisition of MPC adds another manufacturing and sales base outside Japan, following previous acquisitions of biopharmaceutical CDMO companies Biomeva in 2016 and CMC Biologics in 2017. AGC will continue to seek new opportunities and invest in its synthetic and biopharmaceutical businesses to better serve the pharmaceutical industry and its stakeholders.
